Key US patent for Mesoblast treatment

Company News

Mesoblast (ASX: MSB) announced that the US Patent and Trademark Office (USPTO) has granted a key patent covering use of the Company’s proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues.

US Patent No. 9,169,466, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, provides commercial rights in the US through to 8 January 2025 in line with adjustments.

Further patent term extension may occur along with regulatory exclusivity extensions.

The granted claims cover the use of the Company’s allogeneic or off-the-shelf MPCs obtained from any source, for use in conditions including ischemic heart disease, stroke and peripheral arterial disease.

Mesoblast has also been previously granted patents in Europe (EP1613335) and Japan (2006- 503990), derived from the same patent family, which provides the Company with exclusive commercial rights in these two other major healthcare markets to at least 29 March 2024.

This newly granted patent extends and broadens Mesoblast’s intellectual property position in the US with respect to the treatment of cardiac and vascular diseases beyond the previously granted patents thatcover allogeneic culture-expanded Mesenchymal Stem Cell product candidates for cardiovascular diseases.

Mesoblast said it has more than 661 patents or patent applications across at least 72 patent families which provide substantial competitive advantages for the